Cancer guidelines questioned in study

The National Comprehensive Cancer Network often publishes clinical practice guidelines that help shape the course of treatment for cancer patients and insurance coverage. According to a new study published in the journal BMJ on Wednesday, the strength of evidence referenced by the US-based group, referred to as the NCCN, when formulating guidelines and making recommendations appears to be weak. The study found that recommendations may include using a drug for a type of cancer for which it wasn't necessarily approved by the US Food and Drug Administration, also known as "off-label" use, which is widely practiced in oncology care.

More videos